4/1
01:39 pm
hrow
Harrow, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $69.00 to $65.00. They now have a "buy" rating on the stock.
Low
Report
Harrow, Inc. (NASDAQ: HROW) had its price target lowered by analysts at B. Riley from $69.00 to $65.00. They now have a "buy" rating on the stock.
3/31
08:16 am
hrow
Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Low
Report
Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
3/27
04:23 pm
hrow
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results [Yahoo! Finance]
High
Report
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results [Yahoo! Finance]
3/27
04:01 pm
hrow
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
Medium
Report
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
3/27
10:45 am
hrow
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
Low
Report
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
3/24
07:06 am
hrow
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL [Yahoo! Finance]
Medium
Report
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL [Yahoo! Finance]
3/24
07:00 am
hrow
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
Medium
Report
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
3/19
05:20 pm
hrow
Harrow: A Name I Am Accumulating [Seeking Alpha]
Low
Report
Harrow: A Name I Am Accumulating [Seeking Alpha]
3/18
01:23 pm
hrow
Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Low
Report
Harrow, Inc. (NASDAQ: HROW) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
3/17
04:01 pm
hrow
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
High
Report
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
3/17
07:07 am
hrow
Harrow Launches VEVYE® Access for All [Yahoo! Finance]
Low
Report
Harrow Launches VEVYE® Access for All [Yahoo! Finance]
3/17
07:00 am
hrow
Harrow Launches VEVYE® Access for All
Low
Report
Harrow Launches VEVYE® Access for All
3/11
07:10 am
hrow
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® [Yahoo! Finance]
Medium
Report
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE® [Yahoo! Finance]
3/11
07:00 am
hrow
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
Medium
Report
Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®
3/3
07:15 am
hrow
Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025
Medium
Report
Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025
2/20
07:37 am
hrow
NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires [Yahoo! Finance]
Low
Report
NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires [Yahoo! Finance]
2/19
01:48 pm
hrow
Implied Volatility Surging for Harrow (HROW) Stock Options [Yahoo! Finance]
Low
Report
Implied Volatility Surging for Harrow (HROW) Stock Options [Yahoo! Finance]
2/6
07:33 am
hrow
Harrow, Inc. (NASDAQ: HROW) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $57.00 price target on the stock.
Low
Report
Harrow, Inc. (NASDAQ: HROW) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $57.00 price target on the stock.
1/27
07:30 am
hrow
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
Low
Report
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
1/7
07:00 am
hrow
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer
Low
Report
Harrow Appoints Amir H. Shojaei as Chief Scientific Officer